COVID-19, antibiotics and One Health: a UK environmental risk assessment
dc.contributor.author | Comber, Sean | |
dc.contributor.author | Upton, Mathew | |
dc.contributor.author | Lewin, S | |
dc.contributor.author | Powell, N | |
dc.contributor.author | Hutchinson, Tom | |
dc.date.accessioned | 2020-10-08T10:47:44Z | |
dc.date.issued | 2020-08-12 | |
dc.identifier.issn | 0305-7453 | |
dc.identifier.issn | 1460-2091 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/16493 | |
dc.description.abstract |
There is growing interest in the role of secondary bacterial and fungal infections as a cause of increased morbidity and mortality in COVID-19 patients,1 with reports of up to 95% of COVID-19 inpatients being prescribed antibiotics.2 Concerns have been raised over the environmental implications of such a large-scale drug administration3 and statements made about the potential impacts of COVID-19-related antibiotic prescription on antimicrobial resistance (AMR) and other toxicological effects on the environment.4 The UK National Strategy aims for a world in which AMR is effectively contained, controlled and mitigated by 2040.5 Taking a ‘One Health’ approach to effective stewardship in settings such as those being experienced in the current pandemic will be key to minimizing the negative impacts of antibiotic use. A large proportion of some drugs (and metabolites) are excreted by patients into wastewater treatment works (WwTW), leading to release of drug residues into effluent-receiving rivers and coastal waters. Environmental concentrations and impacts will be greatest where drugs are used in high volumes, pass through WwTW largely undegraded and are discharged into rivers with limited dilution. | |
dc.format.extent | 3411-3412 | |
dc.format.medium | ||
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Oxford University Press (OUP) | |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
dc.subject | Anti-Bacterial Agents | |
dc.subject | Betacoronavirus | |
dc.subject | COVID-19 | |
dc.subject | Coronavirus Infections | |
dc.subject | Drug Resistance, Bacterial | |
dc.subject | Environmental Pollutants | |
dc.subject | Humans | |
dc.subject | One Health | |
dc.subject | Pandemics | |
dc.subject | Pneumonia, Viral | |
dc.subject | Risk Assessment | |
dc.subject | SARS-CoV-2 | |
dc.subject | United Kingdom | |
dc.subject | Water Pollutants, Chemical | |
dc.title | COVID-19, antibiotics and One Health: a UK environmental risk assessment | |
dc.type | journal-article | |
dc.type | Journal Article | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000593065400048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 11 | |
plymouth.volume | 75 | |
plymouth.publication-status | Published | |
plymouth.journal | Journal of Antimicrobial Chemotherapy | |
dc.identifier.doi | 10.1093/jac/dkaa338 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/School of Biomedical Sciences | |
plymouth.organisational-group | /Plymouth/Faculty of Science and Engineering | |
plymouth.organisational-group | /Plymouth/Faculty of Science and Engineering/School of Geography, Earth and Environmental Sciences | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA06 Agriculture, Veterinary and Food Science | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/BEACh | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Research Groups/Marine Institute | |
plymouth.organisational-group | /Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR) | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
plymouth.organisational-group | /Plymouth/Users by role/Researchers in ResearchFish submission | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2020-07-15 | |
dc.rights.embargodate | 2020-10-14 | |
dc.identifier.eissn | 1460-2091 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1093/jac/dkaa338 | |
rioxxterms.licenseref.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
rioxxterms.licenseref.startdate | 2020-08-12 | |
rioxxterms.type | Journal Article/Review |